ВПЛИВ КОМБІНАЦІЇ ТІОТРОПІЮ/ОЛОДАТЕРОЛУ НА ФУНКЦІЮ ЗОВНІШНЬОГО ДИХАННЯ У ХВОРИХ НА ХОЗЛ В РЕАЛЬНІЙ КЛІНІЧНІЙ ПРАКТИЦІ

Abstract

EFFECT OF COMBINATION OF TIOTROPIUM/OLODATEROL ON PULMONARY FUNCTION IN PATIENTS WITH COPD IN THE REAL CLINICAL PRACTICE Y. M. Mostovoy, K. D. Dmytriiev, N. S. Slepchenko Abstract Aim — to evaluate the effect of combination therapy with tiotropium/olodaterol on pulmonary function in real clinical practice. Materials and methods. 100 patients with the diagnosis of COPD were included into the study (mean age was 64,09±1,94 years, 66 men and 34 women). Smokers — 68 %, mean smoking duration (24,44 ± 4,84) packyears. Average COPD duration was 9,35±2,42 years. All patients underwent spirometry at screening, 4-6 weeks and at 1 year after inclusion. FEV1, FVC, FEV1/FVC, FEF25, FEF50, FEF75, PEF, MMEF75/85, FEF75/85 were calculated. Results. There was statistically significant improvement in FEV1 and FVC values between visits 1 and 3 (p < 0,05). At visit 3 there was a statistically significant difference in FEV1 and FVC values when compared with same values at visit 1 after the inhalation of salbutamol, demonstrating better bronchodilation effect of tiotropium/olodaterol. Absolute increase of FEV1 between visits 1 and 3 was 221,31±34,9 ml; FVC — 411,01±66,08 ml. There was statistically significant increase of FEF75, MMEF75/25, FEF75/85 between visits 1 and 3 (p < 0,05). There was statistically significant increase of FEF75 at visits 2 and 3 in comparison with postBD FEF75 at visit, confirming better bronchodilation effect of tiotropium/olodaterol combination of at the level of small bronchi when compared with salbutamol (p < 0,05). Conclusions. Tiotropium/olodaterol combination showed good effect on pulmonary function in patients with COPD in real clinical settings. This combination demonstrated better bronchodilation than salbutamol, especially at the level of small bronchi. Key words: COPD, tiotropium/olodaterol, spirometry. Ukr. Pulmonol. J. 2020;29(3):28–30.